热门资讯> 正文
Ardelyx提供商业进展最新信息;股价上涨8%
2025-01-14 01:32
- Ardelyx (NASDAQ:ARDX), on Monday, provided an update on the company’s progress in 2024 and initial expectations for 2025.
- The company achieved significant commercial progress in 2024, finishing with total U.S. net product sales revenue of approximately $319M(unaudited).
- The company reaffirmed peak U.S. net IBSRELA sales revenue of greater than $1B, and announced peak U.S. net XPHOZAH sales revenue of $750M.
- Ardelyx (NASDAQ:ARDX) finished 2024 with approximately $250M in cash, cash equivalents and investments (unaudited).
- In 2025, the company will focus on continued commercial execution to maintain the strong momentum for IBSRELA.
- Ardelyx currently expects full-year 2025 U.S. net product sales revenue for IBSRELA to be between $240.0 and $250.0 million.
- Ardelyx continues to expect IBSRELA to achieve greater than ten percent market share at peak and generate more than $1.0 billion in annual U.S. net product sales revenue before patent term expiration.
- Ardelyx (ARDX) shares were up more than 8% during Monday trading hours.
More on Ardelyx
- Ardelyx: A Small Bet Its Latest Setback Will Be Temporary
- Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It
- Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability
- Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop
- Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update)
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
